logo
Twitter
Discord
Email
logo
Compass Therapeutics, Inc.

Compass Therapeutics, Inc.

NASDAQ•CMPX
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-04-05
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Contact Information
80 Guest Street, Suite 601, Boston, MA, 02135, United States
617-500-8099
www.compasstherapeutics.com
Market Cap
$713.43M
P/E (TTM)
-10.8
42.1
Dividend Yield
--
52W High
$5.86
52W Low
$1.33
52W Range
85%
Rank71Top 96.3%
1.4
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.10+31.23%
4-Quarter Trend

FCF

$0.00-100.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Liquidity Position Maintained Cash, equivalents, and securities total $220M USD; expected to fund operations into 2028 based on current plans.
R&D Spending Rises Sharply Nine-month R&D expenses reached $42.3M USD, increasing $13.0M USD, driven by pipeline advancement costs.
Recent Equity Financing Secured August 2025 offering provided $129.3M USD net proceeds, bolstering capital resources for ongoing clinical development.
Increased Net Loss Reported Nine-month net loss widened to $(50.8)M USD from $(34.3)M USD, reflecting increased operating expenses.

Risk Factors

Continued Operating Losses Expected Expect significant expenses for years ahead advancing pipeline; profitability timing remains highly unpredictable.
Drug Pricing Executive Actions New executive orders target drug price reduction, potentially impacting future reimbursement and commercial viability.
Global Economic Uncertainty Risk Global market instability, inflation, and trade disputes pose risks that may adversely affect financial results.
Dependence on Future Funding Substantial additional funding required to support operations; failure to raise capital risks delaying development efforts.

Outlook

Tovecimig Data Expected Q1 2026 Overall survival and progression-free survival analysis for Tovecimig BTC Phase 2/3 study anticipated in late Q1 2026.
CTX-8371 Data Presentation Planned Full topline data for CTX-8371 Phase 1 study expected at medical meeting during first half of 2026.
Pipeline Expansion Initiated Planning cohort expansions this quarter for NSCLC and TNBC indications based on previously observed responses.
Increased G&A Anticipated Anticipate general and administrative expenses will increase as headcount grows to support overall business operations.

Peer Comparison

Revenue (TTM)

REGENXBIO Inc.RGNX
$161.32M
+91.3%
Arcturus Therapeutics Holdings Inc.ARCT
$92.04M
-35.4%
MeiraGTx Holdings plcMGTX
$27.42M
+96.8%

Gross Margin (Latest Quarter)

REGENXBIO Inc.RGNX
80.7%
+31.9pp
KalVista Pharmaceuticals, Inc.KALV
58.6%
+0.0pp
MeiraGTx Holdings plcMGTX
23.7%
+33.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SVRA$1.41B-13.6-69.1%18.1%
KOD$1.26B-8.1-176.6%28.5%
MLTX$942.76M-5.3-41.6%16.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:-$0.10
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.10+31.2%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.14+47.4%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.12+51.9%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $850.00K+0.0%
    |
    EPS: $-0.36-9.1%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.08-2.6%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 12, 2024|
    Revenue: $850.00K+0.0%
    |
    EPS: $-0.10+6.7%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.08+67.4%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 21, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.33+5.7%
    N/A